Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 3, 2025Premier Journal of CardiologyOpen Access

SGLT2 inhibitors, novel devices, and AI expand therapeutic options and improve heart failure outcomes.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Heart failure causes considerable morbidity, mortality, and healthcare expenditure, with many advances emerging in the last decade requiring a concise evidence overview for clinical decision-making.

Design

Narrative review

Key result

Recent advancements in heart failure management, including SGLT-2 inhibitors, novel medical devices, and artificial intelligence, have expanded therapeutic options and improved patient outcomes.

Authors

SSSaheed E. Sanyaolu

Discussion

Loading...

Member takes

Overview

May inform HF guideline updates; leaves open need for RCTs confirming benefits of devices and AI.

Structured PICO

P
Population
Patients with heart failure
I
Intervention
Emerging treatment approaches for heart failure, including new drugs, precision medicine through genome editing, and artificial intelligence-based innovations
C
Comparator
Traditional treatment strategies

This narrative review summarizes recent advancements in heart failure management, highlighting new pharmacological therapies, precision medicine, and AI innovations.

Limitations

  • Emerging concerns regarding the affordability and accessibility of new treatment strategies
  • Ethical dilemmas and potential adverse effects associated with experimental treatments
  • Publication bias favoring positive results while underreporting inherent risks

Cite This Study

Saheed E. Sanyaolu (2025) conducted a review in Heart failure. Recent advancements in heart failure management, including SGLT-2 inhibitors, novel medical devices, and artificial intelligence, have expanded therapeutic options and improved patient outcomes.

synapsesocial.com/papers/6a1307fc1100fc8528c0b835https://doi.org/10.70389/pjc.100008
View Full Paper
Ask AI
Bookmark
Share